Sweden
· Delayed Price · Currency is SEK CombiGene AB Statistics
Total Valuation
CombiGene AB has a market cap or net worth of SEK 47.72 million. The enterprise value is -26.03 million.
| Market Cap | 47.72M |
| Enterprise Value | -26.03M |
Important Dates
The next estimated earnings date is Friday, August 22, 2025.
| Earnings Date | Aug 22, 2025 |
| Ex-Dividend Date | Jun 13, 2025 |
Share Statistics
CombiGene AB has 19.80 million shares outstanding.
| Current Share Class | 19.80M |
| Shares Outstanding | 19.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.23% |
| Owned by Institutions (%) | 16.62% |
| Float | 16.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.87 |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.58 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.47
| Current Ratio | 17.47 |
| Quick Ratio | 17.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -47.73% and return on invested capital (ROIC) is -25.21%.
| Return on Equity (ROE) | -47.73% |
| Return on Assets (ROA) | -24.12% |
| Return on Invested Capital (ROIC) | -25.21% |
| Return on Capital Employed (ROCE) | -52.97% |
| Revenue Per Employee | 222,132 |
| Profits Per Employee | -4.99M |
| Employee Count | 9 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.26% in the last 52 weeks. The beta is 1.22, so CombiGene AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | -22.26% |
| 50-Day Moving Average | 2.47 |
| 200-Day Moving Average | 2.47 |
| Relative Strength Index (RSI) | 45.65 |
| Average Volume (20 Days) | 11,148 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CombiGene AB had revenue of SEK 2.00 million and -44.88 million in losses. Loss per share was -2.27.
| Revenue | 2.00M |
| Gross Profit | -17.57M |
| Operating Income | -37.92M |
| Pretax Income | -44.88M |
| Net Income | -44.88M |
| EBITDA | -32.12M |
| EBIT | -37.92M |
| Loss Per Share | -2.27 |
Balance Sheet
The company has 73.75 million in cash and n/a in debt, giving a net cash position of 73.75 million or 3.72 per share.
| Cash & Cash Equivalents | 73.75M |
| Total Debt | n/a |
| Net Cash | 73.75M |
| Net Cash Per Share | 3.72 |
| Equity (Book Value) | 71.58M |
| Book Value Per Share | 3.61 |
| Working Capital | 70.82M |
Cash Flow
| Operating Cash Flow | -29.95M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,896.65% |
| Pretax Margin | -2,244.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 8.00%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 8.00% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 8.00% |
| Earnings Yield | -94.04% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 7, 2021. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jun 7, 2021 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
CombiGene AB has an Altman Z-Score of 4.98 and a Piotroski F-Score of 1.
| Altman Z-Score | 4.98 |
| Piotroski F-Score | 1 |